Last reviewed 2026-04-23 · How we verify

Course B3 +Vin

Course B3 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents to disrupt cancer cell division and induce apoptosis in pediatric malignancies.

Course B3 + Vin is a combination chemotherapy regimen that uses vincristine (Vin) alongside other agents to disrupt cancer cell division and induce apoptosis in pediatric malignancies. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric lymphomas and other hematologic malignancies.

At a glance

Mechanism of action

This is a multi-agent chemotherapy combination where vincristine acts as a vinca alkaloid that inhibits microtubule formation, preventing mitotic spindle assembly and causing cell cycle arrest. The 'Course B3' component likely refers to a standardized protocol block used in pediatric cancer treatment regimens, combining vincristine with additional chemotherapeutic agents to achieve synergistic cytotoxic effects against rapidly dividing cancer cells.

Approved indications

• Pediatric acute lymphoblastic leukemia (ALL)
• Pediatric lymphomas and other hematologic malignancies

Common side effects

• Peripheral neuropathy
• Myelosuppression
• Nausea and vomiting
• Alopecia
• Constipation

Key clinical trials

• CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Course B3 +Vin CI brief — competitive landscape report
• Course B3 +Vin updates RSS · CI watch RSS
• Children's Cancer Group, China portfolio CI